See the DrugPatentWatch profile for keytruda

Keytruda, a cancer medication manufactured by Merck & Co., was initially mainly focused on treating melanoma when it was launched. Melanoma is a type of skin cancer that can spread rapidly if not detected and treated early.

According to DrugPatentWatch.com, Keytruda was first approved by the US Food and Drug Administration (FDA) in September 2014 for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.

Since its initial launch, Keytruda has received additional FDA approvals for the treatment of other types of cancer, including non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, and microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer.

Sources:

* <https://www.drugpatentwatch.com/drugs/keytruda>